![]() The move by officials prompted investors to unload Chinese stocks listed in the U.S.Īnalysts told Reuters that despite the fact that U.S.Keep, Ximalaya, and LinkDoc call off their US IPO plans - PingWest English 中文 LinkDoc Technology, the China-based healthcare data technology provider that counts e-commerce group Alibaba as an investor, filed yesterday to raise up to 100m in an initial public offering in the United States. LinkDoc is likely the first Chinese startup to have retreated from its IPO plans as China’s regulatory agencies stepped up Big Tech oversight. The sources declined to be named as the information has not yet been made public yet.īeijing-based LinkDoc did not immediately respond to a request for comment.The Alibaba Health-backed medical data technology and services provider has chosen the US for its planned initial public offering. The book closed one day earlier than planned on Wednesday, two of the sources said. LinkDoc filed for an initial public offering in the United States last month and was due to price its. The deal would have raised $211 million at the upper end of the indicated range. LinkDoc Technology, which is backed by Alibaba Health (BABA) filed, filed for an IPO to raise 100m, although that’s likely just a placeholder value.Medical data company LinkDoc wrote in. One of the sources said the regulatory uncertainty affected both the company and investors. July 8 - Medical data group LinkDoc Technology becomes the first Chinese company to pull back from plans to list in the United States after regulators started an investigation into Didi. It had planned to sell 10.8 million shares between $17.50 and $19.50 each. ![]() Didi, which offers services in China and more than 15 international markets, gathers vast amounts of real-time mobility data every day. Trading session since Chinese regulators ordered its app off mobile app stores in China. LinkDoc filed for an initial public offering in the United States last month and was due to price its shares after the U.S. Tim has been a China-based contributor for publications including The Sunday Times. treatment for HER2-positive breast cancer, has been investigated but did not show. The decision to pull the LinkDoc deal was due to the crackdown, the sources said. and liquid biopsy sources, including circulating tumor DNA (ctDNA). Two weeks ago, Chinese ride-hailing big Didi Chuxing debuted in New York and raised 4.4 billion. It is the first known Chinese firm to pull back from its IPO plans since the crackdown began last week with an investigation by China's cybersecurity regulator into ride-hailing giant Didi Global Inc (DIDI.N) just two days after it made its New York debut.īeijing said on Tuesday that it would strengthen supervision of all Chinese firms listed offshore, a sweeping regulatory shift that triggered a sell-off in U.S.-listed Chinese stocks. But Didi’s listing is probably going the last major IPO by a Chinese firm in the U.S. HONG KONG, July 8 (Reuters) - Chinese medical data group LinkDoc Technology Ltd (LDOC.O) has shelved plans for an IPO in the United States following Beijing's clampdown on overseas listings by domestic firms, according to three sources with direct knowledge of the matter.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |